Dyslipidemia Therapeutics: Market Research Report

Date: April 22, 2010
Pages: 429
Price:
US$ 3,950.00
Publisher: Global Industry Analysts, Inc
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: D10381A5EBAEN
Leaflet:

Download PDF Leaflet

Dyslipidemia Therapeutics: Market Research Report
This report analyzes the worldwide markets for Dyslipidemia Therapeutics in US$ Million by the following segments - Statins, and Non-Statins.

The report provides separate comprehensive analytics for US, Japan, Europe, and Rest of World.

Annual estimates and forecasts are provided for each region for the period 2006 through 2015.

The report profiles 41 companies including many key and niche players worldwide such as Abbott Laboratories, AstraZeneca, PLC, GlaxoSmithKline, Inc., Merck & Co., Inc., Mylan, Inc., Novartis AG, Pfizer, Inc., and Teva Pharmaceutical Industries Ltd.

Market data and analytics are derived from primary and secondary research.

Company profiles are mostly extracted from URL research and reported select online sources.
I.INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study
Statins
Non-Statins

II. EXECUTIVE SUMMARY

1.GLOBAL MARKET OVERVIEW

Outlook
Global Market Analysis
Plummeting Growth for Statins
Non-Statin Drug Segment to Drive Future Growth
Major Drugs Face Patent Expiry
Major Dyslipidemia Drugs & Patent Expiry
Key Challenges Faced by Dyslipidemia Market
Patents Expiry
Generic Penetration

Table 1. Increasing Penetration of Generics in the US and European Dyslipidemia Therapeutics Market by Volume (2005-2009) (includes corresponding Graph/Chart)

Strict FDA Regulations
Pipeline Drugs: Focused on Unmet Needs
List of Select Pipeline Drugs for Treatment of Dyslipidemia (2009)
Novel Combination Products and Future Therapies to Change Landscape
Fixed-Dose Combination Therapies
Simcor - The Foremost Fixed-Dose Combination

CERTRIAD

Combination Therapy – Treatment for Diabetic Dyslipidemia
Market Competition and Brand Dynamics
Lipitor – Top Selling Statin

Table 2. Lipitor Sales Worldwide (2004-2008) (In US$ Billion) (includes corresponding Graph/Chart)

Crestor – The Rising Statin

Table 3. Crestor Sales Worldwide (2004-2008) (In US$ Billion) (includes corresponding Graph/Chart)

Vytorin (Ezetimibe/Simvastatin)
Lovaza – The Leading Non-Statin
Trilipix –The Foremost Combination Therapy Drug

Table 4. Leading Non-Statin Brands in the US and Europe (2009): Percentage Breakdown of Value Sales for Tricor, Niaspan, Lovaza, Antara, Triplix and Others (includes corresponding Graph/Chart)

2.DYSLIPIDEMIA – AN INSIGHT

Introduction to Dyslipidemia
Classification
Causes
Hereditary Dyslipidemia
Types
Familial Combined hyperlipidemia
Familial Hypertriglyceridemia
Familial Dysbetalipoproteinemia
Hypoalphalipoproteinemia
Symptoms of Dyslipidemia
Co-morbid Disorders and Risk Factors
Diagnosis
Treatment Strategies
Drug Therapy

3.TREATMENT OF DYSLIPIDEMIA

Classes of Antidyslipidemic Drugs
Statins
Types of Statins
Various Types of Statins Along With Their Brand Names and Availability in Market as Prescription Generic Drugs
Growth Drivers for Statins
Impediments to Growth
Non-Statins
Types of Non-Statins
Fibric Acid Derivatives
Bile Acid Sequestrants
Cholesterol Absorption Inhibitors
Potential Growth Drivers for Non-Statins
Market Opportunities
Non-Statin Products in Pipeline
Select Non -Statin Drugs in Pipeline (2009)
Lipoprotein Synthesis Inhibitor
Fat Supplements

4.PRODUCT APPROVALS AND CLINICAL TRIALS

Kowa Pharmaceuticals America Receives FDA Approval for Livalo
Aegerion Pharmaceuticals Releases Final Data for Lomitapide (AEGR-733) Phase II Trials
Dr Reddy's Laboratories Obtains Approval for Two Drugs
Arena Pharmaceuticals Commences Phase II Clinical Trial for Niacin Receptor Agonist
Abbott Laboratories and Solvay Pharmaceuticals Receives FDA Approval for Trilipix
AstraZeneca and Abbott Submit NDA for CERTRIAD™
Amarin Secures FDA Approval for AMR101 Phase III Trials
Abbott's Receives Approval for using TRILIPIX® as a Combination Therapy
Takeda Commences Phase III Trial for ATL-962
AAIPharma Licenses ProCR Oral Drug Delivery Technology to Cortria
Essentialis Finishes Patient Enrolment Process
Metabolex Releases Results from Phase II Clinical Trial for MBX-8025
Karo Bio Releases Phase II Study Results for Eprotirome
Merck Sharp & Dohme Receives Approval for Tredaptive
Merck Obtains Patent Approval for Two Drugs
Resverlogix Completes Phase 1a Trials for RVX-208
Abbott Obtains Approval from FDA for Simcor
Surface Logix Releases Results of Phase 2a Clinical Trial for SLx-4090
Merck’s Cholesterol Pill to Receive FDA Approval in 2013
Schering-Plough Obtains Approval for Marketing ZETIA®

5.RECENT INDUSTRY ACTIVITY

Abbott and Solvay Group Enter into Definitive Agreement
Daiichi Sankyo Establishes New Subsidiary
AstraZeneca Introduces Crestor
Kowa Takes Over ProEthic Pharmaceuticals
Ore Pharmaceuticals Acquires Exclusive Rights from Roche to Develop Romazarit
AstraZeneca Enters into Agreement with Abbott
Pfizer Sells Esperion Therapeutics
Merck Establishes New Biotechnology Division
GlaxoSmithKline Acquires Reliant Pharmaceuticals

6.FOCUS ON SELECT GLOBAL PLAYERS

Abbott Laboratories (US)
AstraZeneca, PLC (UK)
GlaxoSmithKline, Inc. (US)
Merck & Co., Inc. (US)
Mylan, Inc. (US)
Novartis AG (Switzerland)
Pfizer, Inc. (US)
Teva Pharmaceutical Industries Ltd. (Israel)

7.GLOBAL MARKET PERSPECTIVE

Table 5. World Recent Past, Current & Future Analysis for Dyslipidemia Therapeutics by Geographic Region/Country – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
Table 6. World 10-Year Perspective for Dyslipidemia Therapeutics by Geographic Region/Country – Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart)
Table 7. World Recent Past, Current & Future Analysis for Statins by Geographic Region/Country – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
Table 8. World 10-Year Perspective for Statins by Geographic Region/ Country – Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart)
Table 9. World Recent Past, Current & Future Analysis for Non-Statins by Geographic Region/Country – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
Table 10. World 10-Year Perspective for Non-Statins by Geographic Region/ Country – Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart)

III. MARKET

1.THE UNITED STATES

A. MARKET ANALYSIS

Outlook
Demographics
Dyslipidemia in Elderly Population
Market Share Statistics

Table 11. The US Market for Antidyslipidemic Drugs (2007): Percentage Share Breakdown of Leading Brands by Prescription - Lipitor, Vytorin, Zetia, Crestor, Tricor, Niaspan and, Others (includes corresponding Graph/Chart)

Product Approvals And Clinical Trials
Strategic Corporate Developments
Key Players

B. MARKET ANALYTICS

Table 12. US Recent Past, Current & Future Analysis for Dyslipidemia Therapeutics by Product Segment – Statins and Non-Statins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
Table 13. US 10-Year Perspective for Dyslipidemia Therapeutics by Product Segment –– Percentage Breakdown of Dollar Sales for Statins and Non-Statins Markets for 2006, 2009, and 2015

2.JAPAN

A. MARKET ANALYSIS

Strategic Corporate Developments

B. MARKET ANALYTICS

Table 14. Japanese Recent Past, Current & Future Analysis for Dyslipidemia Therapeutics by Product Segment – Statins and Non-Statins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
Table 15. Japanese 10-Year Perspective for Dyslipidemia Therapeutics by Product Segment – Percentage Breakdown of Dollar Sales for Statins and Non-Statins Markets for 2006, 2009, and 2015

3.EUROPE

A. MARKET ANALYSIS

Strategic Corporate Developments

B. MARKET ANALYTICS

Table 16. European Recent Past, Current & Future Analysis for Dyslipidemia Therapeutics by Geographic Region – France, Germany, Italy, UK, Spain, & Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
Table 17. European 10-Year Perspective for Dyslipidemia Therapeutics by Geographic Region –Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, & Rest of Europe Markets for 2006, 2009, and 2015 (includes corresponding Graph/Chart)
Table 18. European Recent Past, Current & Future Analysis for Dyslipidemia Therapeutics by Product Segment – Statins and Non-Statins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
Table 19. European 10-Year Perspective for Dyslipidemia Therapeutics by Product Segment – Percentage Breakdown of Dollar Sales for Statins and Non-Statins Markets for 2006, 2009, and 2015

3A.FRANCE

Market Analysis

Table 20. French Recent Past, Current & Future Analysis for Dyslipidemia Therapeutics by Product Segment – Statins and Non-Statins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
Table 21. French 10-Year Perspective for Dyslipidemia Therapeutics by Product Segment – Percentage Breakdown of Dollar Sales for Statins and Non-Statins Markets for 2006, 2009, and 2015

3B.GERMANY

Market Analysis

Table 22. German Recent Past, Current & Future Analysis for Dyslipidemia Therapeutics by Product Segment – Statins and Non-Statins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
Table 23. German 10-Year Perspective for Dyslipidemia Therapeutics by Product Segment – Percentage Breakdown of Dollar Sales for Statins and Non-Statins Markets for 2006, 2009, and 2015

3C.ITALY

Market Analysis

Table 24. Italian Recent Past, Current & Future Analysis for Dyslipidemia Therapeutics by Product Segment – Statins and Non-Statins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
Table 25. Italian 10-Year Perspective for Dyslipidemia Therapeutics by Product Segment – Percentage Breakdown of Dollar Sales for Statins and Non-Statins Markets for 2006, 2009, and 2015

3D.THE UNITED KINGDOM

Market Analysis

Table 26. UK Recent Past, Current & Future Analysis for Dyslipidemia Therapeutics by Product Segment – Statins and Non-Statins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
Table 27. UK 10-Year Perspective for Dyslipidemia Therapeutics by Product Segment – Percentage Breakdown of Dollar Sales for Statins and Non-Statins Markets for 2006, 2009, and 2015

3E.SPAIN

Market Analysis

Table 28. Spanish Recent Past, Current & Future Analysis for Dyslipidemia Therapeutics by Product Segment – Statins and Non-Statins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
Table 29. Spanish 10-Year Perspective for Dyslipidemia Therapeutics by Product Segment – Percentage Breakdown of Dollar Sales for Statins and Non-Statins Markets for 2006, 2009, and 2015

3F.REST OF EUROPE

Market Analysis

Table 30. Rest of Europe Recent Past, Current & Future Analysis for Dyslipidemia Therapeutics by Product Segment – Statins and Non-Statins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
Table 31. Rest of Europe 10-Year Perspective for Dyslipidemia Therapeutics by Product Segment – Percentage Breakdown of Dollar Sales for Statins and Non-Statins Markets for 2006, 2009, and 2015

4.REST OF WORLD

A. MARKET ANALYSIS

China
Outlook
Key Players
Strategic Corporate Developments

B. MARKET ANALYTICS

Table 32. Rest of World Recent Past, Current & Future Analysis for Dyslipidemia Therapeutics by Product Segment – Statins and Non-Statins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
Table 33. Rest of World 10-Year Perspective for Dyslipidemia Therapeutics by Product Segment – Percentage Breakdown of Dollar Sales for Statins and Non-Statins Markets for 2006, 2009, and 2015

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 41 (including Divisions/Subsidiaries - 43)
Region/CountryPlayers
The United States23
Canada
Japan
Europe
France
The United Kingdom
Italy
Rest of Europe
Asia-Pacific (Excluding Japan)
Middle-East
Skip to top


Dyslipidemia - Pipeline Review, H2 2016 US$ 2,000.00 Aug, 2016 · 339 pages
Mixed Dyslipidemia - Pipeline Review, H2 2014 US$ 1,600.00 Nov, 2014 · 56 pages

Ask Your Question

Dyslipidemia Therapeutics: Market Research Report
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: